TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

About this update from Trisalus Life Sciences, Inc.

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples WESTMINSTER, Colo., June 10, 2026--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating that Pressure-Enabled Drug Delivery™ (PEDD™) delivered a 48% improvement in drug delivery to target tumors while reducing complications associated with off-target administration when compared with conventional embolization approaches — results with meaningful implications for the estimated 900,000 patients diagnosed annually worldwide with primary liver tumors or liver metastases. Alexander S. Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital (Newport Beach, CA), will join TriSalus management to discuss the current treatment landscape for hepatocellular carcinoma (HCC) and liver metastases, how the new real-world evidence shapes patient selection and treatment strategy, and share clinical experience and case examples using the TriNav® Infusion System. A live Q&A session will follow the formal presentations, providing direct engagement with management and Dr. Misono. "The publication of this real-world evidence marks an important milestone in demonstrating the clinical and economic value of PEDD™ technology for patients undergoing liver embolization. We look forward to a rich discussion with Dr. Misono on how these findings can help interventional oncologists optimize treatment decisions and improve outcomes for their patients." — Mary Szela, President & CEO, TriSalus Life Sciences The TriNav® Infusion System is one of three FDA-cleared devices in the TriSalus platform that utilize the PEDD™ approach to deliver therapeutics directly to liver and pancreatic tumors. The technology is designed to modulate pressure and flow to maximize drug delivery to the tumor while reducing undesired ...

View stock analysis, news, and events for Trisalus Life Sciences, Inc.